Summary of HR 5127: PrEP and PEP are Prevention Act

Purpose and Intent

The PrEP and PEP are Prevention Act (HR 5127) aims to enhance access to pre-exposure prophylaxis (PrEP) and post-exposure prophylaxis (PEP) medications for the prevention of HIV. The bill seeks to address barriers that individuals face in obtaining these critical medications, thereby promoting public health and reducing the incidence of HIV infections across the United States.

Key Provisions

While the specific text of the bill is not provided, the following key provisions are anticipated based on the bill's title and intent:

• Increased Access: The bill is likely to propose measures that would improve access to PrEP and PEP medications, potentially including:

  • Insurance coverage mandates for PrEP and PEP.
  • Elimination of cost-sharing for patients using these preventive medications.

• Education and Awareness: The legislation may include initiatives aimed at increasing awareness and education about the benefits of PrEP and PEP, targeting both healthcare providers and at-risk populations.

• Funding for Programs: The bill could allocate federal funding to support programs that facilitate access to PrEP and PEP, particularly in underserved communities.

• Data Collection and Reporting: Provisions may be included for the collection of data on the use and effectiveness of PrEP and PEP, which would help inform future public health strategies.

Affected Parties

The PrEP and PEP are Prevention Act would primarily affect:

• Individuals at Risk for HIV: Those who are at high risk for HIV infection would benefit from improved access to preventive medications.
• Healthcare Providers: Medical professionals would receive guidance and resources to better educate patients about PrEP and PEP.
• Insurance Companies: Insurers may be required to adjust their coverage policies to comply with the mandates set forth in the bill.

Legislative Process and Timeline

• Introduced: The bill was introduced in the House of Representatives on September 4, 2025.
• Committee Referral: It has been referred to the Committee on Energy and Commerce, as well as the Committees on Ways and Means, and Oversight and Government Reform for further consideration. The timeline for committee review will be determined by the Speaker of the House.

Sponsors

The bill is sponsored by Maxine Waters and has a significant number of cosponsors, including notable representatives such as:

• LaMonica McIver
• Nikema Williams
• Sylvia R. Garcia
• Joyce Beatty
• Frederica S. Wilson

This broad support indicates a strong commitment among lawmakers to address HIV prevention through enhanced access to PrEP and PEP.

Conclusion

The PrEP and PEP are Prevention Act represents a proactive approach to combating HIV infections in the U.S. by improving access to preventive medications. As the bill progresses through the legislative process, it will be important to monitor its developments and the potential impact on public health initiatives.